glp-1 weight loss drug news today october 2025 What to watch for in drugs in 2026: Price changes, pills and more Rhode Island considers ending Medicaid
Description
Its worth noting that retatrutides safety profile appears broadly consistent with other peptide-based treatments like semaglutide and tirzepatide, which also carry gastrointestinal considerations
Intravenous infusion of GLP-1 for 48 h in healthy human subjects increased muscle sympathetic nerve activity but had no effect on BP, norepinephrine plasma concentration, or the sympathetic/parasympathetic balance as estimated by the HR variability, suggesting that the increase in sympathetic drive is at least partially compensated by an increase in the parasympathetic activity [53]
People with BMIs of 35 or higher automatically qualify
Additionally, obesity rates alone are expected to increase from 14% to 24% within this timeframe, potentially impacting nearly 2 billion adults, adolescents, and children by 2035
Importantly, they dont act on GLP-1 receptors the way prescription medications do
[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al
